CaseVuVerified with MSK: BCR::ABL1 Total MRD Coverage & 0.0001% Sensitivity
Catch rare variants missed by standard p210 assays.
- The Quad-Multiplex Advantage: Most labs only monitor p210.
12.3% of p210 patients carry multiple or rare isoforms (p190, p203, p230). If you aren’t testing for all four, you risk of drug resistance or a silent relapse - Sensitivity (0.0001%): High-sensitivity monitoring is no longer optional; it is the prerequisite for AMP-aligned Treatment-Free Remission (TFR) protocols. Most of the standard p210 assays LOD is 1×10^-4.5, while our assay is 1×10^-5
- Single-Well Efficiency: Run all 4 isoforms in a single plate on your standard RT-PCR platform (QuantStudio). No new CAPEX required
- Verified with MSK: Evaluated and verified in a joint study with Memorial Sloan Kettering (MSK), our panel is specifically designed to identify these rare and multiple isoforms with industry-leading precision
- The Hybrid Advantage: Don’t choose between a kit and a service. Precipio offers both. Start by sending samples to our CAP/CLIA lab to clear your backlog. When you’re ready, transition the testing to your own bench. We provide the validation and training, and remain your permanent clinical backup
Bloodhound BCR-ABL1 panel has been validated as a lab developed test at Precipio. It has not been approved by the FDA.
Tech Overview BCR-ABL1 SDS
Development Of Bloodhound BCR-ABL1 Panel
Precipio’s clinical hematopathology laboratory developed the Bloodhound BCR-ABL1 molecular panel to enhance turn-around time and provide more accurate, comprehensive BCR-ABL molecular testing. By adopting a panel approach to gene mutation detection and MRD monitoring, Precipio’s clinical lab efficiently identifies single mutations, mutation changes, and co-expression across four BCR-ABL1 breakpoints (p.190, p.203, p.210, and p.230) in a single assay on one RT-PCR platform. As a result, our lab achieves a more efficient testing workflow, which in turn enables rapid turn-around times. All this while providing more molecular information to clinicians.
BCR-ABL1 Molecular Panel Configurations
The BCR-ABL1 panel comes pre-plated or as reagent sets with optimized primers and embedded mutant, NTC, and wild type controls for p.190, p.203, p.210, and p.230 breakpoints. This simplifies lab inventory management by providing a complete molecular assay without tracking multiple SKUs of single gene testing assays that require separate control kits. This also means fewer lot to lot QC checks are required compared to individual assays for each breakpoint that is tested.
- 4-Sample pre-plated plate
- 8-Sample pre-plated plate
- Vialed free flow reagent set
BCR-ABL1 Assay Workflow
The process begins with standard RNA isolation and cDNA preparation techniques to prepare the sample. Next, data is captured on the RT-PCR instrument and uploaded for automated analysis, which determines the presence and relative ratio of the p.190, p.203, p.210, and p.230 breakpoints.